
Pre-made Moxetumomab benchmark antibody ( Fv Fusion, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-358
Pre-Made Moxetumomab biosimilar, Fv Fusion, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Moxetumomab pasudotox-tdfk injection is used to treat hairy cell leukemia that has worsened or cannot be completely removed in patients who have had at least two previous treatments that did not work well.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-358-1mg | 1mg | Inquiry | ||
GMP-Bios-ab-358-10mg | 10mg | Inquiry | ||
GMP-Bios-ab-358-100mg | 100mg | Inquiry | ||
GMP-Bios-ab-358-xmg | >100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Moxetumomab biosimilar, Fv Fusion, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody |
INN Name | Moxetumomab |
Target | CD22 |
Format | Fv Fusion |
Derivation | |
Species Reactivity | Human |
CH1 Isotype | na |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Approved |
Est. Status | NFD |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2009 |
Year Recommended | 2010 |
Companies | National Cancer Institute (USA);AstraZeneca;M. D. Anderson Cancer Center;MedImmune;National Cancer Institute (USA) |
Conditions Approved | Hairy cell leukaemia |
Conditions Active | na |
Conditions Discontinued | Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma |
Development Tech | CAT Phage Display |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
